Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:ELYM NASDAQ:NVLN NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.54-1.3%$1.60$1.03▼$2.41$48.04M-0.53429,811 shs99,202 shsELYMEliem Therapeutics$1.70+17.2%$1.36$2.35▼$11.55$50.58M-0.39486,688 shs4.70 million shsNVLNNovelion Therapeutics$0.70$0.54▼$2.35$13.77M2.12190,529 shs26,947 shsPYRGFPyroGenesis Canada$0.28-0.2%$0.33$0.25▼$0.71$52.45M0.8312,768 shs39,309 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-1.28%-4.35%-2.53%+4.05%-26.14%ELYMEliem Therapeutics0.00%+12.58%+32.81%+42.86%-71.90%NVLNNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%PYRGFPyroGenesis Canada-0.21%-1.10%-19.89%-13.85%-47.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals2.0555 of 5 stars3.55.00.00.00.00.00.6ELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada0.3301 of 5 stars0.04.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50192.21% UpsideELYMEliem Therapeutics 0.00N/AN/AN/ANVLNNovelion Therapeutics 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVLN, PYRGF, ELYM, and ATNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ANVLNNovelion Therapeutics$130.43M0.00N/AN/A($4.69) per share0.00PYRGFPyroGenesis Canada$9.14M5.74N/AN/A($0.01) per share-28.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/AELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/ANVLNNovelion Therapeutics-$108.33MN/A0.00N/AN/A-79.43%N/A-26.13%N/APYRGFPyroGenesis Canada-$21.12M-$0.01N/A∞N/A-115.14%N/A-60.81%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25ELYMEliem TherapeuticsN/A60.4160.41NVLNNovelion TherapeuticsN/A0.240.21PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%ELYMEliem Therapeutics69.76%NVLNNovelion Therapeutics35.00%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%ELYMEliem Therapeutics4.70%NVLNNovelion Therapeutics3.60%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableNVLNNovelion Therapeutics10919.62 millionN/AOptionablePYRGFPyroGenesis Canada90187.31 million96.34 millionNo DataNVLN, PYRGF, ELYM, and ATNM HeadlinesRecent News About These CompaniesPyroGenesis Announces Second Quarter 2025 ResultsAugust 6 at 9:00 PM | globenewswire.comPyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch TechnologyAugust 5, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What HappenedAugust 3, 2025 | marketbeat.comPyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference CallAugust 1, 2025 | globenewswire.comPyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing CompanyJuly 31, 2025 | globenewswire.comPyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed SilicaJuly 28, 2025 | globenewswire.comPyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata SteelJuly 15, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Stock Price Up 1.2% - Here's What HappenedJuly 10, 2025 | marketbeat.comPyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production CyclesJuly 8, 2025 | globenewswire.comPyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in EuropeJuly 2, 2025 | globenewswire.comPyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - MorningstarJune 29, 2025 | morningstar.comMPyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 27, 2025 | globenewswire.comPyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global SupplierJune 12, 2025 | globenewswire.comPyroGenesis Announces Extension to Term of WarrantsJune 9, 2025 | globenewswire.comHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29, 2025 | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28, 2025 | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPyroGenesis Announces First Quarter 2025 ResultsMay 13, 2025 | globenewswire.comPyroGenesis Provides Update on Fumed Silica ProjectMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVLN, PYRGF, ELYM, and ATNM Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.54 -0.02 (-1.28%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.32%) As of 08/8/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Eliem Therapeutics NASDAQ:ELYM$1.70 +0.25 (+17.24%) As of 08/4/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Novelion Therapeutics NASDAQ:NVLNNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.PyroGenesis Canada NASDAQ:PYRGF$0.28 0.00 (-0.21%) As of 08/8/2025 02:54 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
